← Back to Search

Metoprolol for Coronary Artery Disease (POINT-NOCAD Trial)

N/A

Waitlist Available

Led By Nathaniel Smilowitz, MD

Research Sponsored by NYU Langone Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Stable ischemic heart disease OR acute myocardial infarction as the indication for coronary angiography

Adult age ≥18 years referred for clinically indicated coronary angiography

Must not have

Clinical Exclusion criteria: Estimated glomerular filtration rate < 45 mL/min

Timeline

Screening 3 weeks

Treatment Varies

Follow Up visit 1, day 0

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing if a anti-inflammatory drug can help patients with ischemic heart disease who have non-obstructive coronary artery disease.

Who is the study for?

This trial is for adults over 18 with stable ischemic heart disease or acute myocardial infarction needing coronary angiography. It's not for those with poor kidney function, allergies to iodine contrast media, pregnant individuals, or anyone with significant blockage in their heart arteries.

What is being tested?

The study tests if Metoprolol (a beta-blocker), Isovue and Nitroglycerin (both related to imaging procedures), along with CCTA scans can help understand inflammation in patients who have chest pain but no major artery blockages.

What are the potential side effects?

Metoprolol may cause tiredness, dizziness, and cold hands/feet. Isovue might lead to allergic reactions or warmth during the scan. Nitroglycerin can cause headaches and low blood pressure. CCTA involves radiation exposure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have stable heart disease or had a recent heart attack.

Select...

I am 18 or older and have been referred for a heart artery check.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

My kidney function is normal or only mildly reduced.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ visit 1, day 0

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~visit 1, day 0

This trial's timeline: 3 weeks for screening, Varies for treatment, and visit 1, day 0 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Perivascular coronary fat attenuation in patients with MINOCA will be greatest in the culprit coronary vessels with evidence of acute plaque disruption.

Perivascular coronary fat attenuation will be greater in INOCA patients with versus without coronary microvascular disease

Perivascular coronary fat attenuation will be significantly greater in MINOCA patients compared with INOCA patients

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Intervention groupExperimental Treatment4 Interventions

Participants will be identified by review of the cardiac catheterization laboratory schedule each day by the principal investigator, a co-investigator, or a research coordinator. Participants with no obstructive CAD and completed microvascular testing will undergo a research CCTA.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Nitroglycerin

2006

Completed Phase 4

~2250

Coronary computed tomography angiography (CCTA)

2022

N/A

~140